
    
      Examination of pirfenidone (EsbrietÂ®) therapy in coal workers' pneumoconiosis with pulmonary
      fibrosis associated with radiographic and functional impairment to examine the reduction in
      progression of disease, reduction of exacerbation rates and possible reduction of
      inflammatory biomarkers as an index of clinical response.
    
  